WHC is still in active development. Read this to understand our approach.
depiction of JZQKKSLKJUAGIC-UHFFFAOYSA-N.svg
isomerdesign

Pindolol

Verificar en isomerdesign

pubchem

Pindolol

Verificar en pubchem

drugmap

Pindolol

Verificar en drugmap

wiki

Pindolol

Verificar en wiki

Data

InChI: InChI=1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3

Sinónimos: Pindolol (JP17/USP/INN),Lopac0_000955, LB-46,Calvisken,5-21-03-00017 (Beilstein Handbook Reference),Tox21_110221_1,Pindolol [USAN:USP:INN:BAN:JAN],PINDOLOL [VANDF],Glauco-visken, Pectobloc (TN),EN300-18518413,DSSTox_RID_77043,NCGC00015786-06, Blocklin-L, 1-(Indol-4-yloxy)-3-(isopropylamino)-2-propanol,NCGC00261640-01,Carvisken (TN),AB00052072_12,SR-01000000027-5,LB-46,KBio1_000837,KBio2_004157, (1)-1-(1H-Indol-4-yloxy)-3-(isopropylamino)propan-2-ol,Prestwick3_000090,FT-0673907,Blockin L,4-(3-(Isopropylamino)-2-hydroxypropoxy)indole,NCGC00015786-10,NSC 757276,MLS002548891,AB00052072, Pindololum,Dl-lb-46,Durapindol,4-(2-Hydroxy-3-isopropylaminopropoxy)-indole,CAS-13523-86-9, DL-4-[2-Hydroxy-3-(isopropylamino)propoxy]indole, Pynastin (TN),(+/-)-LB-46,1-((1-Methylethyl)amino)-3-(4-indolyloxy)-2-propanol,PINDOLOL [ORANGE BOOK],HMS2089I21,NCGC00024925-04,2-Propanol, 1-(indol-4-yloxy)-3-(isopropylamino)-,N-(2-HYDROXY-3-(1H-INDOL-4-YLOXY)PROPYL)-N-ISOPROPYLAMINE,Spectrum3_000547,HMS3414J03, P 0778, (+-)-Pindolol, Cardilate (TN),PINDOLOL [MART.],Apo-pindol,(+-)-Pindolol,HMS502J19,PINDOLOL [MI],BRD-A97701745-001-09-5,Prestwick1_000090, 4-(3-(Isopropylamino)-2-hydroxypropoxy)indole, 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol,NCGC00015786-08,SCHEMBL5219,PINDOLOL,(-),1-(1H-Indol-4-yloxy)-3-(isopropylamino)-2-propanol #,(-)-Pindolol; (S)-(-)-Pindolol; S-Pindolol,1-(1H-Indol-4-yloxy)-3-isopropylamino-propan-2-ol((-)-Pindolol),NCGC00024925-06,1-(4-Indolyloxy)-3-(isopropylamino)-2-propanol,SW196641-3,1-(1H-Indol-4-yloxy)-3-[(1-methylethyl)amino]-2-propanol,HMS1920H16,BRD-A97701745-001-05-3,CCRIS 9215,NCGC00015786-14,1-(1H-Indol-4-yloxy)-3-isopropylamino-propan-2-ol,2-Propanol, 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]-,Pindololum,Q418101,PINDOLOL [USP MONOGRAPH],2-Propanol, 1-(indol-4-yloxy)-3-(isopropylamino)-, (+-)-, Calvisken, 4-(2-Hydroxy-3-isopropylaminopropoxy)-indole,Spectrum2_001285,(rs)-pindolol, Durapindol (TN), Carvisken (TN),Pectobloc,Pindololum [INN-Latin],Spectrum5_001266,pindolol,C07445,l-Pindolol,SB17015,Tox21_500955, 1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol,Pynastin,KBioGR_000958,1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol,1-((1H-indol-4-yl)oxy)-3-(isopropylamino)propan-2-ol, Glauco-visken, Blockin L,BDBM50019443,Spectrum_001109,PINDOLOL [JAN],LP00955,C90604,DL-Pindolol,KBio2_006725, 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol,HMS3262P12,Blocklin-L, Decreten,Tox21_110221,SPBio_001289,BJ4HF6IU1D,CHEMBL500,SMR000059120,BPBio1_000022,(+/-)-4-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)INDOLE, Pindolol [USAN:INN:BAN:JAN],Blocklin,Pindolol, United States Pharmacopeia (USP) Reference Standard, Durapindol,SR-01000000027-2,AB00052072_13, LB46,KBioSS_001589,PINDOLOL [USP-RS],Prinodolol, LB 46,Pindolol,1-(1H-Indol-4-yloxy)-3-((1-methylethyl)amino)-2-propanol,BSPBio_002193,PINDOLOL [HSDB],Carvisken,PDSP2_000760, Decreten (TN),Prestwick2_000090,HMS1568A22,NCGC00024925-03,SR-01000000027,1-(1H-indol-4-yloxy)-3-[(propan-2-yl)amino]propan-2-ol,UNII-BJ4HF6IU1D, Calvisken (TN),13523-86-9,NCGC00015786-22,DL-4-[2-Hydroxy-3-(isopropylamino)propoxy]indole,2-Propanol, 1-(1H-indol-4-yloxy)-3-((1-methylethyl)amino)-,(+/-)-PINDOLOL, Visken (TN), Glauco-Viskin, DL-LB 46, Pindolol (JP15/USP/INN),PDSP1_000771, 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol,PDSP2_000759,CCG-39223,1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol,PINDOLOL [INN],HMS3742C07, Betapindol (TN),CHEBI:8214,NINDS_000837,PINDOLOL [EP MONOGRAPH],Blocklin-L (TN),PDSP1_000772,PINDOLOL COMPONENT OF VISKAZIDE,SBI-0050929.P004,1-(Indol-4-yloxy)-3-(isopropylamino)-2-propanol,EINECS 236-867-9, Blocklin L, Pynastin,BS-42390, Blocklin, Prinodolol,Blocklin L, Blocklin-L (TN), Carvisken,PINDOLOL [USAN],DL-LB 46,Glauco-Viskin,HMS3267K17,Betapindol,P 0778,NCGC00015786-07, P-6820, 1-((1-Methylethyl)amino)-3-(4-indolyloxy)-2-propanol,HMS3885N04,DSSTox_GSID_23476,KBio3_001693,NCGC00015786-16,NCGC00015786-09,AB00052072-11,PINDOLOL [WHO-DD],P-6820,Visken,Pharmakon1600-01500488,4-(3-Isopropylamino-2-hydroxypropoxy)indole,1-(1H-Indol-4-yloxy)-3-isopropylamino-propan-2-ol(pindolol),HSDB 6539,AKOS015969756,IDI1_000837,523P869,LB 46,NCGC00024925-07,Spectrum4_000479,D00513,HMS3678H21,NCGC00015786-11, Pindololum [INN-Latin],1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol, Blockin L (TN),NC00467,NSC757276, Pectobloc,Oprea1_770884,NCGC00015786-13,4-(2-HYDROXY-3-ISOPROPYLAMINOPROPOXY)INDOLE, 1-(1H-Indol-4-yloxy)-3-[(1-methylethyl)amino]-2-propanol,2-Propanol, 1-(1H-indol-4-yloxy)-3-(1-methylethyl)amino-, 1-(1H-Indol-4-yloxy)-3-(isopropylamino)-2-propanol,Visken (TN),GTPL91,BSPBio_000020, DL-Pindolol,SPBio_001959,SPECTRUM1500488,(1)-1-(1H-Indol-4-yloxy)-3-(isopropylamino)propan-2-ol,NCGC00015786-20, Blocklin L (TN),EU-0100955,SR-01000000027-7, Prindolol (TN), 1-(1H-indol-4-yloxy)-3-[(propan-2-yl)amino]propan-2-ol,HMS2095A22,HMS3259I07,SDCCGSBI-0050929.P005,HMS2091P20, Pinbetol, 1-(1H-Indol-4-yloxy)-3-((1-methylethyl)amino)-2-propanol,NSC-757276,SR-01000000027-4,NCGC00024925-05,CS-4473,DSSTox_CID_3476,DL-4-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)INDOLE,L000006,DivK1c_000837,2-Propanol, 1-(4-indolyloxy)-3-(isopropylamino)-,KBio2_001589, Pinbetol (TN),Prestwick_397,Pinbetol,Prestwick0_000090,(.+/-.)-Pindolol,Pindolol, >=98% (TLC), powder,Decreten,(+/-)-Pindolol-d7(iso-propyl-d7),HY-B0982,HMS3712A22, Visken,Pindolol, European Pharmacopoeia (EP) Reference Standard,DTXSID8023476,DB00960, Prindolol,BRN 1536506,EINECS 244-623-8,MLS000069496, Glauco-Visken (TN),1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol,VISKAZIDE COMPONENT PINDOLOL,HMS3369E14

Estimated data

Solubilidad: -1.459 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 43.5% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.